Loading...
Adults with relapsed or refractory acute lymphoblastic leukemia (ALL) typically have short survival with currently available therapies. In an industry-sponsored, multicenter, prospective, randomized, phase III trial, investigators compared the single-agent, CD22-targeting antibody-drug conjugate inotuzumab ozogamicin (IO) with standard second-line induction chemotherapy regimens in 326 adult B-cell ALL patients; two thirds had failed one prior induction, and one third had failed two or more. Responding patients could proceed to allogeneic stem cell transplantation (SCT) at the investigator's discretion.
Progression-free survival was increased with IO versus standard re-induction therapy (5.0 vs. 1.8 months; P<0.001), as was overall survival …